Tanvex Biopharma, Inc.

Tanvex Biopharma, Inc.

TTWSE:6541
26.80
TWD
-0.70
(-2.55%)
-5.59EPS
10.63BMarket Cap
Mar 10Next Earn
Tanvex Biopharma, Inc.
TWSE:6541
(Taiwan Stock Exchange)

Recent

price

26.80

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
- -
- -
- -
- -
- -
- -
- -
- -
0.05
0.19
0.47
0.22
1.64
2.51
Revenue per Share
-9.77
-7.47
-16.42
-18.22
-20.29
-23.31
-26.48
-22.43
-13.68
-13.71
-16.44
-8.9
-6.13
-5.59
Basic EPS, GAAP
-9.38
-16.66
-20.8
-15.84
-19.12
-21.1
-23.2
-19.77
-12.57
-11.94
-11.59
-8.13
-6.84
-6.67
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
6.33
9.25
22.72
51.06
47.73
48.26
32.14
24.05
22.89
11.39
6.02
5.4
21.5
18.74
Book Value per Share
5.67
8.52
21.79
50.24
47.42
48.05
31.97
23.94
22.8
11.29
6
5.36
8.68
5.88
Tangible Book Value per Share
31
35
51
68
69
81
86
94
113
120
130
155
245
262
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
5
22
61
35
401
658
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
-699,859
-29,581.65
-7,166.21
-3,420.8
-3,912.4
-344.59
-214.98
Operating Margin (%)
23
40
67
118
133
143
216
220
244
282
325
289
367
348
Depreciation Expense
-299
-265
-835
-1,244
-1,410
-1,894
-2,274
-2,104
-1,543
-1,641
-2,137
-1,382
-1,500
-1,465
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
-701,412
-28,546.26
-7,325.17
-3,480
-3,983.94
-374.13
-222.84
Profit Margin (%)
120
174
678
2,720
3,011
3,487
2,335
1,910
2,153
740
240
327
698
385
Working Capital
- -
- -
- -
- -
- -
- -
272
1,399
1,670
1,715
1,568
1,488
1,367
1,758
LT Debt
404
590
1,448
3,573
3,749
4,215
3,031
2,621
2,795
1,391
821
893
5,694
4,966
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-53.27
-81.98
-49.57
-38.51
-47.56
-62.77
-74.47
-56.99
-78.41
-193.18
-161.17
-45.55
-29.78
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
212
325
326
LT Borrowings
- -
- -
460
LT Finance Leases
1,367
1,351
1,298
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
265
265
265
Market Capitalization
14,567
10,573
10,626

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,497
1,104
1,209
Cash, Cash Equivalents & STI
879
442
593
Accounts Receivable, Net
30
96
120
Inventories
416
406
332
Total Current Liabilities
800
827
824
Payables & Accruals
- -
- -
- -
ST Debt
212
325
326
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
58.41%
92.33%
537.41%
Free Cash Flow
6.27%
-0.16%
32.84%
Net Income, GAAP
9.24%
-3.37%
8.59%
Sales/Revenue/Turnover
- -
640.66%
1,056.27%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3
17
12
3
35
2025
50
47
125
179
401
2026
133
220
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-3.1
-2.29
-1.94
-1.68
-8.9
2025
-2.09
-1.41
-1.08
-1.59
-6.13
2026
-1.47
-1.44
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Tanvex BioPharma, Inc. is a vertically integrated biopharmaceutical company specializing in the development, manufacturing, and commercialization of biosimilars and biologics. Founded in 2013 and headquartered in the Cayman Islands, Tanvex operates key facilities in San Diego, California, and Taipei, Taiwan. The company’s core products include biosimilars targeting therapeutic areas such as neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. Tanvex also provides contract development and manufacturing organization (CDMO) services under the Bora Biologics brand, offering end-to-end biologics solutions including cell-line development, process development, GMP manufacturing, analytical development, and regulatory support. Its manufacturing capabilities encompass microbial fermentation and mammalian cell culture using state-of-the-art bioreactors and automated purification technologies, enabling the production of biologics with high quality and consistency. In the last two years, Tanvex has undergone significant strategic changes, including the appointment of industry veteran Stephen Lam as CEO in September 2024 to lead global CDMO operations and biosimilar commercialization. The company completed the acquisition of Bora Biologics in January 2025, integrating Bora’s complementary large molecule CDMO services and manufacturing facilities, which expanded Tanvex’s biomanufacturing platform substantially with over 100,000 square feet of facility space and enhanced bioreactor capacity. Bora Pharmaceuticals became the largest shareholder following a strategic investment in mid-2025, supporting Tanvex’s global development and manufacturing capabilities, including new fill/finish services in Maryland, USA. Tanvex’s integrated operations across the US and Asia allow the company to efficiently address evolving market and regulatory demands while advancing its biosimilar and biologics pipeline. Tanvex serves biopharmaceutical companies and healthcare markets globally, leveraging its comprehensive capabilities from R&D to commercial-scale production and regulated market approvals. The company emphasizes innovation and operational efficiency to deliver affordable, effective biologic therapies while maintaining stringent compliance with regulatory standards. Tanvex’s vertical integration strategy allows it to control the entire biopharma production process, ensuring quality, lowering costs, and accelerating time to market for its biosimilars and CDMO clients. The company continues to expand its portfolio and operational footprint with a focus on delivering impactful biopharmaceutical solutions worldwide.